Creative Planning
ODT

Creative Planning’s Odonate Therapeutics, Inc. Common Stock ODT Stock Holding History

Creative Planning’s Portfolio ODT Stock Details ODT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-50,000
Closed -$672K – 2505
2020
Q3 		$672K Buy
+50,000
New +$1.42M ﹤0.01% 980

Other funds holding ODT

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Creative Planning's ODT Position: Q4 2020 in Review

Creative Planning sold out of Odonate Therapeutics, Inc. Common Stock (ODT) in Q4 2020, closing a stake of 50,000 shares — an estimated $672K sold.

Creative Planning first reported a position in ODT in Q3 2020 and held it in 1 quarter. The position peaked at $672K in Q3 2020. 94 funds tracked by Wall St. Rank hold ODT as of Q4 2020.

  • Creative Planning reported no remaining Odonate Therapeutics, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Creative Planning sold 50,000 Odonate Therapeutics, Inc. Common Stock shares in Q4 2020, an estimated $672K.
  • Creative Planning first reported a position in Odonate Therapeutics, Inc. Common Stock in Q3 2020 and held it in 1 quarter.
  • Creative Planning's Odonate Therapeutics, Inc. Common Stock position peaked at $672K in Q3 2020.
  • 94 funds tracked by Wall St. Rank held Odonate Therapeutics, Inc. Common Stock as of Q4 2020.

Based on Creative Planning's 13F filing for Q4 2020, filed 29 Jan 2021.